Flags

Earnings warning

Ascentage Pharma Group

HKG:6855 · KYG0519B1023

BiotechnologyMedium

360

Value38

Profit price51

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price13

Price/Sales7

EV / Gross Profit28

Price/Book4

Quality29

Returns on capital21

Return on Capital37

Cash Return on Capital18

Return on Equity9

Profit margins28

EBIT Margin1

Gross Profitability55

Cash backing26

Accruals17

Owner Earnings Margin34

Growth50

Sales growth94

Profit growth5

Reinvestment77

Price momentum24

Safety50

Debt load3

Debt serviceability9

Refinancing16

Debt Payback1

Liquidity12

Sentiment57

Analyst ratings91

Expectations trend73

Opinion Changes50

Price Target Upside96

Market mood67

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Ascentage Pharma Group clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryChina

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeSEHK

Founded2017

Employees153

Websiteascentage.cn

ISINKYG0519B1023

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

HematologyChronic DiseasesInfectious DiseasesOncologyHepatologyBiopharmaMedicalPharmaceutical

Description

Ascentage Pharma Group International, an integrated biopharmaceutical company, engages in discovering, developing, and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. The company's lead assets…

Analysis

Weak and unloved

Ascentage Pharma Group International is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ascentage Pharma Group with its peers

Kyowa Hakko Kirin

TYO:4151

CountryJapan

IndustryPharmaceuticals

SizeX-Large

Full Stock Analysis →

Medical Developments International

ASX:MVP

CountryAustralia

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Pharmicell

KSC:005690

CountrySouth Korea

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mesoblast

ASX:MSB

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Telix Pharmaceuticals

ASX:TLX

CountryAustralia

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Clinuvel Pharmaceuticals

ASX:CUV

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →